Clover Biopharmaceuticals（HKEX: 2197）

HKEX Filings

• Oct 9, 2022
  INSIDE INFORMATION - CLOVER PROVIDES UPDATE ON 2022 CORPORATE MILESTONES
• Oct 5, 2022
  Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2022
• Sep 20, 2022
  VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE RECEIVES EU GMP CERTIFICATE
• Sep 20, 2022
  VOLUNTARY ANNOUNCEMENT - CLOVER'S UNIVERSAL COVID-19 BOOSTER VACCINE CANDIDATE DEMONSTRATES SUPERIOR NEUTRALIZATION OF OMICORN BA.5 COMPARED TO INACTIVATED VACCINE
• Sep 16, 2022
  Notification Letter and Request Form for Non-Registered Shareholders
• Sep 16, 2022
  2022 Interim Report
• Sep 15, 2022
  VOLUNTARY ANNOUNCEMENT - AMENDMENT TO THE ADVANCE PURCHASE AGREEMENT
• Sep 6, 2022
  VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES SUPERIOR BOOSTER RESPONSES COMPARED TO INACTIVATED VACCINE
• Sep 2, 2022
  Monthly Return of Equity Issuer on Movements in Securities for the Month ended August 31, 2022
• Aug 30, 2022
  VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 BOOSTER VACCINE CANDIDATE DEMONSTRATES ROBUST NEUTRALIZATION OF DOMINANT OMICRON BA.5 SUBVARIANT
• Aug 25, 2022
  VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE 2/3 RESULTS IN ADOLESCENTS FOR CLOVER'S COVID-19 VACCINE
• Aug 24, 2022
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022
• Aug 11, 2022
  DATE OF BOARD MEETING
• Aug 4, 2022
  Monthly Return of Equity Issuer on Movements in Securities for the Month ended July 31, 2022
• Jul 19, 2022
  GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
• Jul 4, 2022
  Monthly Return of Equity Issuer on Movements in Securities for the Month ended June 30, 2022
• Jun 27, 2022
  VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES STRONG CROSS-NEUTRALIZATION AGAINST OMICRON AS A HOMOLOGOUS BOOSTER
• Jun 20, 2022
  LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
• Jun 20, 2022
  APPOINTMENT OF NON-EXECUTIVE DIRECTORS
• Jun 14, 2022
  VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PATIENT WITH SCB-219M IN PHASE 1 TRIAL FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA